Clinical Trial Update: Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study [Phase 4]

View source ↗

Summary

A prospective multicenter Phase 4 trial is assessing the safety and efficacy of combining RIF with Anlotinib in patients with advanced recurrent platinum-resist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• RIF

Snippet

Sponsor: Peking University People's Hospital | Conditions: Platinum-resistant Ovarian Cancer (PROC) | Phase 4 | Status: NOT_YET_RECRUITING